Class information for:
Level 1: OLANZAPINE//WEIGHT GAIN//SERIOUS MENTAL ILLNESS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
618 3157 43.1 77%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
278 18430 RISPERIDONE//CLOZAPINE//OLANZAPINE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 OLANZAPINE Author keyword 39 14% 8% 260
2 WEIGHT GAIN Author keyword 36 11% 10% 307
3 SERIOUS MENTAL ILLNESS Author keyword 17 21% 2% 73
4 ATYPICAL ANTIPSYCHOTICS Author keyword 15 13% 4% 113
5 ANTIPSYCHOTIC AGENTS Author keyword 11 13% 2% 77
6 ANTIPSYCHOT Address 10 73% 0% 8
7 MENTAL HLTH NURSING INNOVAT Address 10 34% 1% 23
8 PHYSICAL HEALTH Author keyword 10 10% 3% 90
9 EARLY PSYCHOSIS PROGRAMME Address 8 100% 0% 5
10 KLIN PSYCHIAT PSYCHOTHER IE GERONTOPSYCHIAT Address 8 100% 0% 5

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 OLANZAPINE 39 14% 8% 260 Search OLANZAPINE Search OLANZAPINE
2 WEIGHT GAIN 36 11% 10% 307 Search WEIGHT+GAIN Search WEIGHT+GAIN
3 SERIOUS MENTAL ILLNESS 17 21% 2% 73 Search SERIOUS+MENTAL+ILLNESS Search SERIOUS+MENTAL+ILLNESS
4 ATYPICAL ANTIPSYCHOTICS 15 13% 4% 113 Search ATYPICAL+ANTIPSYCHOTICS Search ATYPICAL+ANTIPSYCHOTICS
5 ANTIPSYCHOTIC AGENTS 11 13% 2% 77 Search ANTIPSYCHOTIC+AGENTS Search ANTIPSYCHOTIC+AGENTS
6 PHYSICAL HEALTH 10 10% 3% 90 Search PHYSICAL+HEALTH Search PHYSICAL+HEALTH
7 METABOLIC SIDE EFFECTS 7 43% 0% 12 Search METABOLIC+SIDE+EFFECTS Search METABOLIC+SIDE+EFFECTS
8 SECOND GENERATION ANTIPSYCHOTICS 5 17% 1% 28 Search SECOND+GENERATION+ANTIPSYCHOTICS Search SECOND+GENERATION+ANTIPSYCHOTICS
9 ANTIPSYCHOTIC AGENTS SECOND GENERATION 4 67% 0% 4 Search ANTIPSYCHOTIC+AGENTS+SECOND+GENERATION Search ANTIPSYCHOTIC+AGENTS+SECOND+GENERATION
10 FRAMINGHAM FUNCTION 4 75% 0% 3 Search FRAMINGHAM+FUNCTION Search FRAMINGHAM+FUNCTION

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 INDUCED WEIGHT GAIN 299 51% 13% 424
2 CATIE SCHIZOPHRENIA TRIAL 124 84% 2% 68
3 ATYPICAL ANTIPSYCHOTICS 120 19% 18% 567
4 HEALTH PLAN DATABASE 70 87% 1% 34
5 EXCESS MORTALITY 55 22% 7% 219
6 OLANZAPINE 52 13% 12% 384
7 CLOZAPINE USE 45 94% 1% 16
8 5 HT2C RECEPTOR GENE 44 56% 2% 54
9 MEDICAL COMORBIDITY 40 42% 2% 74
10 CATIE SCHIZOPHRENIA 36 79% 1% 23

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Diabetes mellitus and severe mental illness: mechanisms and clinical implications 2015 6 102 67%
Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices 2012 68 86 86%
Second-generation (atypical) antipsychotics and metabolic effects - A comprehensive literature review 2005 739 197 58%
Life expectancy and cardiovascular mortality in persons with schizophrenia 2012 55 26 81%
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) 2009 218 108 65%
A systematic review of correlates of physical activity in patients with schizophrenia 2012 54 47 72%
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles 2008 191 72 64%
"First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects 2015 3 62 50%
Metabolic syndrome in people with schizophrenia: a review 2009 128 93 75%
Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms 2015 3 200 46%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ANTIPSYCHOT 10 73% 0.3% 8
2 MENTAL HLTH NURSING INNOVAT 10 34% 0.7% 23
3 EARLY PSYCHOSIS PROGRAMME 8 100% 0.2% 5
4 KLIN PSYCHIAT PSYCHOTHER IE GERONTOPSYCHIAT 8 100% 0.2% 5
5 CLIN DR AMERICO NEGRETTE 6 80% 0.1% 4
6 LINDEMANN MENTAL HLTH 6 100% 0.1% 4
7 SOLLENTUNA PSYCHIAT POLYCLIN 5 60% 0.2% 6
8 PHARMACOGENET CLIN 5 45% 0.3% 9
9 NEW YORK STATE EXCELLENCE CULTURAL COMPETENCE 4 67% 0.1% 4
10 GGZ WNB 4 75% 0.1% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000141384 MEDICAL CLEARANCE//PHYSICAL MORBIDITY//ACUTE PSYCHIATRIC PATIENTS
2 0.0000093012 CLOZAPINE//RISPERIDONE//OLANZAPINE
3 0.0000083291 SOUR CHERRY SEED EXTRACT//SOUR CHERRY KERNEL//ANTI PSYCHOTIC DRUG
4 0.0000073415 DIAG TREATMENT OBES//PSYCHONEUROIMMUNOL NUTR GENET PSYNUGEN//ADRENAL GLAND VOLUME
5 0.0000067229 ANTIPSYCHOTIC POLYPHARMACY//POLYPHARMACY//TUNKU ABDUL RAHMAN NEUROSCI
6 0.0000057761 JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY//CHRISTIAN SARKINE AUTISM TREATMENT//NISONGER
7 0.0000056862 SERTINDOLE//PSYCHOPHARMACOL VENTURE//TROP TOXINOL UNIT
8 0.0000056558 NICOTINE DEPENDENCE//PROGRAM SMOKERS MENTAL ILLNESS//ADDICT PSYCHIAT
9 0.0000055651 ARIPIPRAZOLE//ASENAPINE//ILOPERIDONE
10 0.0000055335 METH MOUTH//CHRONIC PSYCHIATRIC PATIENTS//BAKIRKOY TRAINING HOSP PSYCHIAT NEUROL NE